Business, energy, technology, markets and global industry news from Business News Today

Spevigo

PharmaDeviceNews Spevigo
Editorial infographic highlighting LEO Pharma’s 21 dermatology research posters covering Anzupgo, Spevigo and Adbry, featuring skin tissue illustrations, clinical research imagery and key highlights on adolescent FDA review, clinical evidence and commercial growth prospects.
Pharma & Biotech

Why LEO Pharma is investing in real-world evidence for difficult dermatological diseases

LEO Pharma presents 21 dermatology posters covering Anzupgo, Spevigo and Adbry. Examine adolescent FDA review, clinical data and growth prospects.

Read More
LEO Pharma’s 10% CER revenue growth, led by expanding dermatology brands including Anzupgo and Spevigo, comes as the company increases investment in its late-stage pipeline and rare skin disease portfolio. Representative image.
Pharma & Biotech

LEO Pharma’s sales engine is accelerating, but its next growth bet is already squeezing margins

LEO Pharma’s strategic brands are surging as dersimelagon expands its pipeline, but heavier investment is putting 2026 margins under pressure.

Read More
Vanda Pharmaceuticals advances imsidolimab for generalized pustular psoriasis after a positive European Medicines Agency orphan drug recommendation, although approval and commercialisation hurdles remain. Representative image.
Pharma & Biotech

Vanda’s imsidolimab has won a rare European advantage, but one approved rival changes the equation

Vanda’s imsidolimab gains an EMA orphan recommendation for GPP, but approval, differentiation and European access remain ahead.

Read More